Trial
NCT05027425
Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Cincinnati
Collaborators
—
Condition
Hepatocellular Carcinoma
Intervention
Durvalumab
Why stopped
The study is closing due to low enrollment and feasibility of the study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-06